DK1848442T3 - 2-methylene-19-nor-(20s-24epi)-1alfa,25-dihydroxyvitamine-d2 - Google Patents

2-methylene-19-nor-(20s-24epi)-1alfa,25-dihydroxyvitamine-d2

Info

Publication number
DK1848442T3
DK1848442T3 DK06734708.8T DK06734708T DK1848442T3 DK 1848442 T3 DK1848442 T3 DK 1848442T3 DK 06734708 T DK06734708 T DK 06734708T DK 1848442 T3 DK1848442 T3 DK 1848442T3
Authority
DK
Denmark
Prior art keywords
24epi
dihydroxyvitamine
1alfa
methylene
compounds
Prior art date
Application number
DK06734708.8T
Other languages
Danish (da)
English (en)
Inventor
Hector F Deluca
Lori A Plum
Margaret Clagett-Dame
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of DK1848442T3 publication Critical patent/DK1848442T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK06734708.8T 2005-02-11 2006-02-10 2-methylene-19-nor-(20s-24epi)-1alfa,25-dihydroxyvitamine-d2 DK1848442T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65204405P 2005-02-11 2005-02-11
PCT/US2006/004679 WO2006086608A1 (en) 2005-02-11 2006-02-10 2-METHYLENE-19-NOR-(20S-24EPI)-1α,25-DIHYDROXYVITAMIN-D2

Publications (1)

Publication Number Publication Date
DK1848442T3 true DK1848442T3 (da) 2012-05-29

Family

ID=36793376

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06734708.8T DK1848442T3 (da) 2005-02-11 2006-02-10 2-methylene-19-nor-(20s-24epi)-1alfa,25-dihydroxyvitamine-d2

Country Status (10)

Country Link
US (1) US7511030B2 (enExample)
EP (1) EP1848442B1 (enExample)
JP (1) JP5036565B2 (enExample)
AT (1) ATE554774T1 (enExample)
AU (1) AU2006213722B2 (enExample)
CA (1) CA2597568A1 (enExample)
DK (1) DK1848442T3 (enExample)
MX (1) MX2007009725A (enExample)
NZ (1) NZ561076A (enExample)
WO (1) WO2006086608A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ545862A (en) * 2003-08-20 2010-01-29 Wisconsin Alumni Res Found 2-Methylene-19-nor-vitamin D2 compounds
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
CA2715811A1 (en) 2008-03-06 2009-09-11 Wisconsin Alumni Research Foundation Methods of increasing epidermal skin thickness by topical administration of a 19-nor containing vitamin d compound
US20110237557A1 (en) * 2010-03-23 2011-09-29 Deluca Hector F Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
US8604009B2 (en) * 2010-03-23 2013-12-10 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3
ES2380477B2 (es) * 2010-10-13 2012-11-16 Universidad De Vigo Procedimiento de obtención de "25-hidroxicetona de windaus" que comprende la reacción de julia-kocienski.
CA2824870C (en) * 2011-06-14 2018-08-14 Wisconsin Alumni Research Foundation 3-desoxy-2-methylene-19-nor-vitamin d analogs and their uses

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588716A (en) * 1984-05-04 1986-05-13 Wisconsin Alumni Research Foundation Method for treating metabolic bone disease in mammals
US4666634A (en) 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
JP2898882B2 (ja) 1993-04-05 1999-06-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物
US5552392A (en) 1993-11-03 1996-09-03 Wisconsin Alumni Research Foundation Method of treating hypoparathyroidism with (20S) vitamin D compounds
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6673782B2 (en) * 1999-04-29 2004-01-06 Wisconsin Alumni Research Foundation Treatment of systemic lupus erythematosis
US6479474B2 (en) * 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
US7704979B2 (en) 2000-09-01 2010-04-27 The University Of Tennessee Research Foundation Materials and methods for the treatment or prevention of obesity
US6384087B1 (en) 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
AU7544501A (en) 2000-09-08 2002-03-22 Wisconsin Alumni Res Found 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
US6627622B2 (en) 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
ATE346839T1 (de) 2002-03-29 2006-12-15 Wisconsin Alumni Res Found Ein verfahren zur herstellung von 1-alpha-hydroxy-2-methylen-19-nor-homopregnacal iferol
US7259143B2 (en) * 2002-09-05 2007-08-21 Wisconsin Alumni Research Foundation Method of extending the dose range of vitamin D compounds
NZ542674A (en) * 2003-04-10 2009-03-31 Wisconsin Alumni Res Found 2-Propylidene-19-nor-vitamin D compounds
NZ545862A (en) * 2003-08-20 2010-01-29 Wisconsin Alumni Res Found 2-Methylene-19-nor-vitamin D2 compounds
WO2005027931A1 (en) 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
WO2005027913A1 (en) 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
CA2539361A1 (en) 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
CA2539357A1 (en) 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
WO2005051396A2 (en) * 2003-11-25 2005-06-09 Deltanoid Pharmaceuticals, Inc. Methods for reducing body fat using vitamin d compounds
WO2005051323A2 (en) * 2003-11-25 2005-06-09 Wisconsin Alumni Research Foundation Vitamin d analogs for obesity prevention and treatment

Also Published As

Publication number Publication date
US7511030B2 (en) 2009-03-31
EP1848442A4 (en) 2010-12-15
JP2008530109A (ja) 2008-08-07
CA2597568A1 (en) 2006-08-17
AU2006213722A1 (en) 2006-08-17
MX2007009725A (es) 2007-09-26
ATE554774T1 (de) 2012-05-15
AU2006213722B2 (en) 2011-09-22
EP1848442B1 (en) 2012-04-25
US20060183721A1 (en) 2006-08-17
EP1848442A1 (en) 2007-10-31
JP5036565B2 (ja) 2012-09-26
NZ561076A (en) 2010-01-29
WO2006086608A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
ATE523487T1 (de) 2-methylen-1-alpha-dihydroxy-19,21-dinor-vitami - d3-analoga und ihre anwendung
WO2008035207A3 (en) 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
CY1110900T1 (el) Χημικες ενωσεις
CY1108275T1 (el) Χημικες ενωσεις
MX2009004707A (es) Piridina carboxamides como inhibidores 11-beta-hsd1.
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
BRPI0815920A2 (pt) Composto, composição farmacêutica, e, uso do composto.
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
EP1765391A4 (en) BACTERIAL COMPOSITIONS FOR THE TREATMENT OF CANCER
MX2009007345A (es) Compuestos con (fenil sustituido), con restos de propenal, sus derivados, actividad biologica y uso del mismo.
CY1112960T1 (el) Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων
WO2006119309A3 (en) 19,26,27-TRINOR-1α,25-DIHYDROXYVITAMIN D3 COMPOUNDS
MX2007006096A (es) 2-metilen-19-nor-(20s)-1a-hidroxi-trishomopregnacalciferol.
WO2006086613A3 (en) 2-METHYLENE-19-NOR- (20S-24S) - 1α, 25-D IHYDROXYVITAMIN-D2
DK1848442T3 (da) 2-methylene-19-nor-(20s-24epi)-1alfa,25-dihydroxyvitamine-d2
BR0311386A (pt) Furancarboxamidas
MX2007006090A (es) 2-metilen-19-nor-(20r)-1a-hidroxi-bishomopregnacalciferol.
AU2011232633A8 (en) (20S)-2-methylene-19-nor-22-dimethyl-1alpha,25- dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22- dimethyl-1alpha,25-hydroxyvitamin D3
WO2008125901A8 (en) 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin d3 and uses thereof
EA200901059A1 (ru) Макролиды на основе эритромицина
DE50311756D1 (de) Mikrobizide oxathiincarboxamide
ATE499942T1 (de) 2-methylen-19,21-dinor-1alpha-hydroxy- bishomopregnacalciferol
WO2008035206A3 (en) 2-methylene-1 alpha-hydroxy-18,19,21-trinorvitamin d3 analogs and uses thereof
BRPI0507107A (pt) compostos que se ligam a fator de crescimento e métodos de uso